Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally developed as antidiabetic agents, have emerged as candidate disease-modifying therapies for Parkinson’s disease (PD) and Alzheimer’s disease (AD), reflecting the widespread expression of GLP-1 receptors across neurons, glia, and the cerebral vasculature. This narrative review synthesizes mechanistic, clinical trial, and biomarker evidence for GLP-1 RAs in PD and AD, based on a literature search of PubMed, Embase, Scopus, and Web of Science, with ClinicalTrials.gov searched separately for trial protocols and results, through May 2026. Preclinical data implicate GLP-1 receptor agonism in anti-neuroinflammatory signaling, mitochondrial preservation, autophagy and proteostasis enhancement, anti-apoptotic effects, synaptic plasticity, cerebrovascular protection, and glymphatic clearance. Clinical evidence in PD is mixed and agent- and formulation-dependent: the phase II Exenatide-PD trial reported a motor benefit that persisted after washout (∼3.5-point between-group difference in MDS-UPDRS Part III), and the phase II LIXIPARK trial (lixisenatide) reported a significant 3.08-point between-group difference (95% CI 0.86–5.30; p = 0.007) favoring lixisenatide, whereas the larger, longer phase III Exenatide-PD3 trial, using an extended-release weekly formulation, found no significant effect on the same endpoint (adjusted coefficient 0.92; 95% CI −1.56 to 3.39; p = 0.47); oral semaglutide is under investigation in the ongoing phase II MOST-ABLE trial. In AD, the phase IIb liraglutide (ELAD) trial did not achieve statistical benefit on either its primary imaging endpoint (cerebral glucose metabolic rate; p = 0.14) or on most secondary cognitive measures, and the phase III semaglutide trials EVOKE and EVOKE+ did not meet their primary CDR-SB endpoint (estimated difference −0.08, 95% CI −0.35 to 0.20, p = 0.57 in EVOKE; 0.10, 95% CI −0.17 to 0.38, p = 0.46 in EVOKE+), despite biomarker signals including reductions in cerebrospinal fluid tau species and inflammatory markers. Comparative pharmacology reveals substantial heterogeneity in central nervous system penetration, receptor engagement, and systemic bioavailability across exenatide, liraglutide, semaglutide, and the imbalanced GLP-1/GIP co-agonist tirzepatide, complicating cross-agent extrapolation. Persistent challenges include separating direct neuroprotection from indirect metabolic and cardiovascular benefit, limited characterization of brain drug exposure, trial durations that may be short relative to the expected latency of a disease-modifying effect, and the absence of validated response biomarkers. We conclude that although the mechanistic and epidemiological rationale for GLP-1 RAs in neurodegeneration remains biologically plausible, current trial evidence does not yet support their use outside clinical trials, irrespective of comorbid diabetes status; future studies should prioritize earlier intervention, biomarker-guided patient selection, adequately powered subgroup analyses, and brain-penetrant formulations.
Wearable Sensor (WS)-based monitoring systems detect minute patient movements/ demands and abnormalities through periodic sensing and imaging. Sensor data observed over different intervals is not constant or available based on operating sequences. Due to variations in data sequences, the analysis process becomes complex, resulting in less precise outputs. To address this problem, an Allied Data Disparity Technique (ADDT) is proposed in this article. This technique identifies the disparity in different monitoring sequences in coherence with the clinical and previous values. Based on the mean disparity, the data requirement for the WS sequence is decided. This decision uses multiple substituted and predicted values obtained from previous instances. Multi-Instance Ensemble Perceptron Learning is used in this decision process, where the substitution instances for clinical and previous outcomes are performed. The ensemble perceptron selects the maximum clinical value correlating sensor data to ensure high sequence prediction. The ensembles are updated based on the highest precision-based WS values for diagnosis. This diagnosis-focused coalition between clinical and predicted WS values is updated periodically for the new precision levels identified.
wearable sensorspatient health monitoringclinical data fusionmissing data imputation
Georgi. It has been recognized as an active phytochemical with specific therapeutic potential and significant pharmacological effects, especially in cancer research. Nevertheless, increasing preclinical data both in vitro and in vivo demonstrate its effectiveness against a broad spectrum of cancers, including breast, ovarian, lung, gastric, colorectal, prostate, renal, glioblastoma, and hematological types. Wogonin exerts its anticancer effects through a complex mechanism that involves the induction of programmed cell death (apoptosis), autophagic modulation, and cell cycle arrest. It also suppresses angiogenesis of tumors, epithelial-mesenchymal transition (EMT), invasion, metastasis, and multidrug resistance effects. The effects are supported by the compound's ability to regulate a variety of oncogenic and tumor-suppressive signaling pathways, particularly PI3K/Akt, STAT3, NF-kB, MAPK, AMPK, and Wnt/beta-catenin. It modulates apoptosis-related proteins (Bax, Bcl-2, PARP, caspases) and transcription factors. Wogonin has been shown to enhance the antitumor effects of established chemotherapeutic agents, and it works synergistically with these drugs in multiple cancer models, with the added benefits of reduced systemic toxicity. Nevertheless, it has poor oral bioavailability and water solubility, which limits its clinical application. Recent advances in nanocarriers and liposomal delivery systems show promise in overcoming pharmacokinetic challenges. This review consolidates available pharmacological, mechanistic, and pharmacokinetic evidence of wogonin, highlights its potential in combination therapies, and identifies research gaps and formulation strategies necessary for advancing this candidate towards clinical development as a novel anticancer agent.
The incidence of suicide, self-harm, and mental crises among teenagers is rising, presenting significant global public health issues. Conventional clinical risk evaluations have inadequate predictive accuracy, often overlooking high-risk adolescents. Machine learning models employing electronic health records provide an innovative method for predicting mental health crises through the integration of intricate clinical data patterns. Hence, this review aims to comprehensively examine and synthesize information about machine learning models created using electronic health record data for predicting suicide attempts, self-harm, or mental hospitalization in teenagers. Adhering to Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) principles, we executed an exhaustive search across six databases (2000-2025) for peer-reviewed research utilizing machine learning algorithms on electronic health record data to predict adolescent mental health crises. The inclusion criteria emphasized structured or unstructured electronic health record inputs, teenage cohorts (ages 10-20), and performance indicators like area under the curve (AUC), sensitivity, or specificity. The Prediction Model Risk of Bias Assessment Tool (PROBAST) was utilized to evaluate the risk of bias. Our search yielded five studies (2019-2024) that satisfied the inclusion criteria. All studies were retrospective cohorts conducted in high-income nations. Structured electronic health record data (e.g., diagnoses, prescriptions) were frequently utilized; two studies included natural language processing. Machine learning models demonstrated moderate to high discrimination (AUC 0.68-0.88), exhibiting optimal performance in short-term suicide prediction with hybrid data inputs. All investigations, however, exhibited a significant risk of bias in the analysis domain owing to insufficient external validation and absent calibration data. The positive predictive values consistently remained modest across all models. Overall, machine learning models demonstrate potential for enhancing adolescent suicide risk classification utilizing electronic health record data, surpassing numerous traditional instruments. Nonetheless, issues of generalizability, ethical constraints, and implementation obstacles remain. Thorough validation, calibration, and equity assessments are necessary prior to incorporation into clinical practice.
adolescent mental healthsuicide risk predictionself-harmelectronic health records
Sepsis is a life-threatening condition, and early recognition in the emergency department (ED) is crucial for reducing mortality. However, traditional ED sepsis screening tools (e.g., Systemic Inflammatory Response Syndrome (SIRS) and quick Sequential Organ Failure Assessment (qSOFA)) often lack sensitivity for early detection. Machine learning (ML)-based early warning systems have been proposed to address this gap by analyzing complex clinical data in real time. To address this, we systematically reviewed studies (2015-2025) assessing ML-based sepsis warning systems in adult EDs. Databases searched included PubMed, Embase, Scopus, and Web of Science. Included studies reported diagnostic performance and/or clinical outcomes. Overall, a total of 11 studies (primarily retrospective, with a few prospective) were included. ML models using vital signs, laboratory results, and electronic health record (EHR) data demonstrated high discrimination for sepsis, with area under the receiver operating characteristic curve (AUROC) values often exceeding 0.80, and outperformed traditional scoring tools. Many provided earlier warnings, often two to four hours before sepsis was clinically recognized. Implementation studies showed that ML-based alerts expedited treatment; one multi-center system reduced time to antibiotics by ~1.8 hours when alerts were promptly addressed. Some reports noted reduced organ failure and mortality. However, evidence of improved patient outcomes remains inconsistent, likely due to study heterogeneity and limited prospective validation. ML-based early warning systems show strong potential for improving sepsis recognition and treatment in EDs. Further multi-center trials are needed to confirm their impact on outcomes and guide safe implementation.
sepsisearly warning systemsmachine learningemergency department
Disease diagnosis is a hot research area in Health Informatics (Healthcare) record data mining and an important step towards achieving generative intelligence (GAI) medical diagnosis. However, health perception data in Healthcare records come from diverse sources, with complex data structures and potential correlations between different types of data over wireless medical sensor networks. There is a challenge in how to integrate heterogeneous data during feature extraction and mining analysis. Only through comprehensive consideration of medical sensing data, personal constitution records, and inter-disease relationship data can relevant hidden features be mined to achieve more accurate diagnoses of various disease categories over wireless medical sensor networks. Therefore, based on the fusion of dynamic and static relationships in multisource health perception data, the disease diagnosis model (DSRF) first solves the heterogeneity problem of dynamic medical sensing data and static constitution records through a dynamic–static relationships fusion algorithm to explore their correlations. Then, it calculates the correlation matrix of multicategory diseases to extract inter-disease dependency relationships. Finally, based on the architecture of gated recurrent unit networks, it integrates various health perception data to accomplish a comprehensive analysis of multisource heterogeneous data. Experimental results on the MIMIC-III clinical dataset in the United States demonstrate that compared to mainstream models of the same type, this model can more accurately diagnose multiple disease categories jointly.
disease diagnosismedical sensor dataheterogeneous data fusionwireless medical sensor networks
L. (NS) is an important medicinal plant of Islamic value. This review highlights the anti-COVID-19 potential, clinical trials, inventions, and patent literature related to NS and its major chemical constituents, like thymoquinone. The literature was collected from different databases, including Pubmed, Espacenet, and Patentscope. The literature supports the efficacy of NS, NS oil (NSO), and its chemical constituents against COVID-19. The clinical data imply that NS and NSO can prevent and treat COVID-19 patients with a faster recovery rate. Several inventions comprising NS and NSO have been claimed in patent applications to prevent/treat COVID-19. The patent literature cites NS as an immunomodulator, antioxidant, anti-inflammatory, a source of anti-SARS-CoV-2 compounds, and a plant having protective effects on the lungs. The available facts indicate that NS, NSO, and its various compositions have all the attributes to be used as a promising remedy to prevent, manage, and treat COVID-19 among high-risk people as well as for the therapy of COVID-19 patients of all age groups as a monotherapy or a combination therapy. Many compositions of NS in combination with countless medicinal herbs and medicines are still unexplored. Accordingly, the authors foresee a bright scope in developing NS-based anti-COVID-19 composition for clinical use in the future.
ABSTRACT: Despite the availability and advancement of diagnostic and treatments with demonstrated benefits in minimizing cardiovascular morbidity and mortality, hypertension control rates remain suboptimal. Therefore, this research aimed to determine the prevalence of uncontrolled BP in rheumatoid arthritis (RA) patients and understand all potential risk factors for uncontrolled BP.We conducted a cross-sectional study on RA patients in 2 rheumatology clinics in 2 public hospitals in Riyadh. Patients' information such as demographics, comorbidities, drug use, and other clinical data were captured through a review of medical records and supplemented by patient interviews. Multivariate logistic regression was utilized for the analysis to identify the significant factors of uncontrolled BP (systolic BP ≥140 mm Hg or diastolic BP ≥90 mm Hg).In total, 834 subjects with RA and concomitant BP were involved in this cross-sectional study. The prevalence of uncontrolled BP was found to be 31.65% among all the study population. Multivariate analysis showed that males, subjects above 60 years of age, and smokers had a distinctly higher occurrence of uncontrolled BP. Among the patients with comorbid conditions, those with obesity, hyperlipidemia, diabetes, anemia, cancer, and reflex or gastroesophageal reflux disease also showed a significantly higher risk of uncontrolled BP (P < .05).The rate of uncontrolled BP was found to be alarmingly high in the study population. Age, gender, smoking, diabetes, obesity, hyperlipidemia, cancer, gastroesophageal reflux disease, and osteoporosis are independently linked with lack of BP control.
BioMed Research International · مجلد 2022 (1) · 3372296-3372296
Healthcare occupies a central role in sustainable societies and has an undeniable impact on the well-being of individuals. However, over the years, various diseases have adversely affected the growth and sustainability of these societies. Among them, heart disease is escalating rapidly in both economically settled and undeveloped nations and leads to fatalities around the globe. To reduce the death ratio caused by this disease, there is a need for a framework to continuously monitor a patient's heart status, essentially doing early detection and prediction of heart disease. This paper proposes a scalable Machine Learning (ML) and Internet of Things-(IoT-) based three-layer architecture to store and process a large amount of clinical data continuously, which is needed for the early detection and monitoring of heart disease. Layer 1 of the proposed framework is used to collect data from IoT wearable/implanted smart sensor nodes, which includes various physiological measures that have significant impact on the deterioration of heart status. Layer 2 stores and processes the patient data on a local web server using various ML classification algorithms. Finally, Layer 3 is used to store the critical data of patients on the cloud. The doctor and other caregivers can access the patient health conditions via an android application, provide services to the patient, and inhibit him/her from further damage. Various performance evaluation measures such as accuracy, sensitivity, specificity, F1-measure, MCC-score, and ROC curve are used to check the efficiency of our proposed IoT-based heart disease prediction framework. It is anticipated that this system will assist the healthcare sector and the doctors in diagnosing heart patients in the initial phases.
heart disease predictionearly detectionInternet of Thingswearable sensors
The COVID-19 pandemic needs no introduction at present. Only a few treatments are available for this disease, including remdesivir and favipiravir. Accordingly, the pharmaceutical industry is striving to develop new treatments for COVID-19. Molnupiravir, an orally active RdRp inhibitor, is in a phase 3 clinical trial against COVID-19. The objective of this review article is to enlighten the researchers working on COVID-19 about the discovery, recent developments, and patents related to molnupiravir. Molnupiravir was originally developed for the treatment of influenza at Emory University, USA. However, this drug has also demonstrated activity against a variety of viruses, including SARS-CoV-2. Now it is being jointly developed by Emory University, Ridgeback Biotherapeutics, and Merck to treat COVID-19. The published clinical data indicate a good safety profile, tolerability, and oral bioavailability of molnupiravir in humans. The patient-compliant oral dosage form of molnupiravir may hit the market in the first or second quarter of 2022. The patent data of molnupiravir revealed its granted compound patent and process-related patent applications. We also anticipate patent filing related to oral dosage forms, inhalers, and a combination of molnupiravir with marketed drugs like remdesivir, favipiravir, and baricitinib. The current pandemic demands a patient compliant, safe, tolerable, and orally effective COVID-19 treatment. The authors believe that molnupiravir meets these requirements and is a breakthrough COVID-19 treatment.
Background: Hepatocellular carcinoma (HCC) is considered the most common type of liver cancer and the fourth leading cause of cancer-related deaths in the world. Since the disease is usually diagnosed at advanced stages, it has poor prognosis. Therefore, reliable biomarkers are urgently needed for early diagnosis and prognostic assessment. Methods: We used genome-wide gene expression profiling datasets from human and rat early HCC (eHCC) samples to perform integrated genomic and network-based analyses, and discovered gene markers that are expressed in blood and conserved in both species. We then used independent gene expression profiling datasets for peripheral blood mononuclear cells (PBMCs) for eHCC patients and from The Cancer Genome Atlas (TCGA) database to estimate the diagnostic and prognostic performance of the identified gene signature. Furthermore, we performed functional enrichment, interaction networks and pathway analyses. Results: We identified 41 significant genes that are expressed in blood and conserved across species in eHCC. We used comprehensive clinical data from over 600 patients with HCC to verify the diagnostic and prognostic value of 41-gene-signature. We developed a prognostic model and a risk score using the 41-geneset that showed that a high prognostic index is linked to a worse disease outcome. Furthermore, our 41-gene signature predicted disease outcome independently of other clinical factors in multivariate regression analysis. Our data reveals a number of cancer-related pathways and hub genes, including EIF4E, H2AFX, CREB1, GSK3B, TGFBR1, and CCNA2, that may be essential for eHCC progression and confirm our gene signature’s ability to detect the disease in its early stages in patients’ biological fluids instead of invasive procedures and its prognostic potential. Conclusion: Our findings indicate that integrated cross-species genomic and network analysis may provide reliable markers that are associated with eHCC that may lead to better diagnosis, prognosis, and treatment options.
International Journal of Advanced Trends in Computer Science and Engineering · مجلد 8 (6) · 3012-3016
Big data denotes large volume datasets that grows exponentially over time and cannot be processed or stored using traditional data management tools.There is a huge amount of new data that is stored daily in all areas of our life.This data needs to be collected and analyzed effectively to streamline the decision-making process.Big data analytics (BDA) are techniques that provide a way to analyze this huge quantity of data with the purpose of drawing conclusions about them by driving the business outcomes and real time decisions.With a wide range of data available in the healthcare sector including financial and clinical data, research and development, management and operational data and critical care units, big data in healthcare can generate meaningful insights to improve overall operational efficiency in the industry.There are various benefits for big data analytics in the health-care industry which encompasses advanced patient care; improved operational efficiency; evaluation of practitioner performance; reduced patient cost and researching cure for diseases.The main objective of this study is to outline the main challenges and opportunities of applying big data in health care and how it can help in transforming the healthcare industry towards the valuebased care.
big data analyticsvalue-based carebig data in healthcareclinical data
BACKGROUND: Community-acquired pneumonia (CAP) is as a major cause for childhood morbidity and mortality worldwide. This study was conducted to investigate the adherence and response of the WHO guidelines for treatment of severe pneumonia. METHOD: A cross-sectional study was conducted in the period of June 2009 to July 2010 at Khartoum Hospital, Sudan. Children admitted and treated for severe pneumonia were enrolled. RESULTS: Only 39 (18.8%) out of 208 enrolled children received prescriptions that were adherent to the WHO guidelines of treatment of severe pneumonia. In logistic regression none of the investigated variable (age, gender, and clinical presentations) was associated with the adherence to the WHO guidelines. There was no significant difference in the response between adherent and non-adherent prescriptions. There was no association between the demographic, clinical data, treatment-adherence to the guidelines and the patients' response. CONCLUSION: There is a poor (18.8%) adherence to the WHO guidelines of the treatment of severe pneumonia in the region regardless to the age, gender and clinical presentation.
severe pneumoniapediatric pneumoniaWHO treatment guidelinesguideline adherence